Skip to the main content.

Cell and Gene Therapy Series. Part 4 - Managing costs and scale-up risks for medical devices

Dr. Dave Seaward : 28 February 2022

Cell and Gene Therapy Series. Part 4 - Managing costs and scale-up risks for medical devices

As we continue to explore the world of cell and gene therapy, we now take a look at managing costs and scale up risks for medical devices.

Author Dave Seward, discusses how the principles of Quality by Design (QbD) and Design for Manufacture (DfM) can be applicable to ATMPs. Read this blog now!
Formulation Freedom in Clinical Development: Why Fill2Weight Matters

Formulation Freedom in Clinical Development: Why Fill2Weight Matters

Chris Webster: 1 June 2026

In early-stage pharmaceutical development, poor powder flow is rarely the root issue, it’s simply a symptom. The real challenge for formulation...

Read More
Pouching solutions for sterile and moisture-sensitive devices

Pouching solutions for sterile and moisture-sensitive devices

David Phasey: 20 May 2026

Pouches are widely used in medical device packaging to provide a sterile barrier when the device itself, or its primary container, cannot inherently...

Read More
Interview with Founder Tom Bailey: Blister Dose Delivery Uniformity (DDU)

Interview with Founder Tom Bailey: Blister Dose Delivery Uniformity (DDU)

Georgia Lewis: 18 May 2026

Dose Delivery Uniformity (DDU) is one of the most persistent challenges in dry-powder inhaler development, and few have tackled it more directly...

Read More